An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers

被引:30
作者
Shamsi, Z [1 ]
Kimber, S [1 ]
Hindmarch, I [1 ]
机构
[1] Univ Surrey, HPRU Med Res Ctr, Guildford GU2 5XP, Surrey, England
关键词
antihistamines; sedation; cognition;
D O I
10.1007/s002280000257
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The cognitive and psychomotor effects of 2.5, 5 and 10 mg cetirizine, a second-generation H-1 receptor antagonist, were compared with loratadine 10, 20 and 40 mg, promethazine 25 mg and placebo in 24 healthy Volunteers in a double-blind, randomised cross-over study. Methods. Following each dose, subjects were required to perform a series of tests of cognitive function and psychomotor performance at 1.5, 3 and 6 h post-dose. The test battery consisted of critical flicker fusion (CFF), choice reaction time (CRT), compensatory tracking task (CTT) and assessment of subjective sedation (LARS). Results: Cetirizine and loratadine at all doses tested were not significantly different from placebo in any of the tests used. However, as expected for a verum, all measures with the exception of CTT were significantly disrupted by promethazine (P < 0.05). Promethazine caused a reduction in CFF threshold at all test points; these differences were significant at 3h and 6h post-dose (P < 0.05). There was also a significant increase in total reaction time at 3 h post-promethazine administration. Subjective reports of sedation were significantly greater following the administration of promethazine at all time points (P < 0.05). Conclusions: These results allow the conclusion that cetirizine at its recommended therapeutic dose of 10 mg is demonstrably free from disruptive effects on aspects of psychomotor and cognitive function in a study where the psychometric assessments have been shown to be sensitive to impairment, as evidenced by the effects of the positive control, promethazine 25 mg.
引用
收藏
页码:865 / 871
页数:7
相关论文
共 44 条
[1]  
ALFORD C, 1989, Medical Science Research, V17, P421
[2]   STUDIES ON THE CENTRAL EFFECTS OF THE H1-ANTAGONIST, LORATADINE [J].
BRADLEY, CM ;
NICHOLSON, AN .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (04) :419-421
[3]   ACUTE AND SUBCHRONIC EFFECTS OF THE H-1-HISTAMINE RECEPTOR ANTAGONIST EBASTINE IN 10, 20 AND 30 MG DOSE, AND TRIPROLIDINE 10 MG ON CAR DRIVING PERFORMANCE [J].
BROOKHUIS, KA ;
DEVRIES, G ;
DEWAARD, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (01) :67-70
[4]   CETIRIZINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL POTENTIAL IN ALLERGIC RHINITIS, POLLEN-INDUCED ASTHMA, AND CHRONIC URTICARIA [J].
CAMPOLIRICHARDS, DM ;
BUCKLEY, MMT ;
FITTON, A .
DRUGS, 1990, 40 (05) :762-781
[5]   PERFORMANCE STUDIES WITH ANTIHISTAMINES [J].
CLARKE, CH ;
NICHOLSON, AN .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 6 (01) :31-35
[6]   THE ACUTE EFFECTS OF ACRIVASTINE (BW825C), A NEW ANTIHISTAMINE, COMPARED WITH TRIPROLIDINE ON MEASURES OF CENTRAL NERVOUS-SYSTEM PERFORMANCE AND SUBJECTIVE EFFECTS [J].
COHEN, AF ;
HAMILTON, M ;
PHILIPSON, R ;
PECK, AW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (04) :381-386
[7]  
CURRAN S, 1992, HUMAN PSYCHOPHARMACO, V3
[8]   LACK OF POTENTIATION BY CETIRIZINE OF ALCOHOL-INDUCED PSYCHOMOTOR DISTURBANCES [J].
DOMS, M ;
VANHULLE, G ;
BAELDE, Y ;
COULIE, P ;
DUPONT, P ;
RIHOUX, JP .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (06) :619-623
[9]   THE RELATIVE ANTIHISTAMINIC AND PSYCHOMOTOR EFFECTS OF HYDROXYZINE AND CETIRIZINE [J].
GENGO, FM ;
DABRONZO, J ;
YURCHAK, A ;
LOVE, S ;
MILLER, JK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (03) :265-272
[10]  
GENGO FM, 1987, ANN ALLERGY, V59, P53